Form 4: Perrigo Executive Grainne Quinn Reports Changes in Beneficial Ownership

EVP and Chief Medical Officer of Perrigo, Grainne Quinn, reports transactions involving ordinary shares and restricted stock units.

Summary

• Grainne Quinn, EVP and Chief Medical Officer of Perrigo Company plc, filed a Form 4 detailing changes in her beneficial ownership of the company's ordinary shares.
• On March 5, 2024, Quinn acquired 1,583 shares through the vesting of restricted stock units at a price of $27.26.
• She also acquired 9,028 ordinary shares at a price of $27.26.
• Concurrent with these acquisitions, she disposed of 824 and 4,695 shares to cover tax obligations at a price of $27.26.
• Following these transactions, Quinn directly owns 19,155 ordinary shares.
• The filing also includes a power of attorney document, effective as of September 29, 2020, granting Todd W. Kingma, Ryan Bradtke, and Victor Torres the authority to execute Forms 3, 4, and 5 on Quinn's behalf.

Sentiment

Score: 6

Explanation: The sentiment is neutral as the document primarily reports routine transactions. The acquisitions are slightly positive, but the disposals offset some of that positivity.

Positives

• The acquisition of shares through vesting and purchase indicates a continued investment in the company by the executive.

Negatives

• The disposal of shares to cover tax obligations, while common, reduces the overall increase in share ownership.

Risks

• There are no specific risks highlighted in this document, as it primarily reports transactions related to share ownership.

Industry Context

Form 4 filings are a routine part of regulatory compliance for corporate insiders, providing transparency into their trading activities and ownership positions. This filing indicates the executive's transactions in Perrigo's stock, which is typical for executives receiving stock-based compensation.

Comparison to Industry Standards

• Form 4 filings are standard practice across publicly traded companies, including Perrigo's competitors in the healthcare sector, such as Teva Pharmaceutical Industries and Mylan (now Viatris).
• The vesting schedules and tax-related disposals are common features of executive compensation packages in line with industry norms.
• The amounts of shares acquired and disposed of are specific to the individual's compensation and tax situation, making direct comparisons challenging without detailed compensation data.

Stakeholder Impact

• The transactions reported may have a minor impact on shareholders by providing insight into executive sentiment and ownership.

Key Dates